Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · Real-Time Price · USD
2.690
-0.100 (-3.58%)
Nov 21, 2024, 4:00 PM EST - Market closed
Inozyme Pharma Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Inozyme Pharma stock have an average target of 16.14, with a low estimate of 14 and a high estimate of 23. The average target predicts an increase of 500.00% from the current stock price of 2.69.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Inozyme Pharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +420.45% | Nov 6, 2024 |
| Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +755.02% | Nov 6, 2024 |
| Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +755.02% | Oct 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +420.45% | Oct 25, 2024 |
| Wedbush | Wedbush | Buy Reiterates $15 | Buy | Reiterates | $15 | +457.62% | Sep 30, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.65
from -1.37
EPS Next Year
-1.65
from -1.65
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 39.1M | ||
| Avg | n/a | n/a | 13.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -1.60 | -1.27 | -1.39 | |
| Avg | -1.65 | -1.65 | -1.77 | |
| Low | -1.68 | -1.96 | -2.19 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.